Prokarium raises $10m for thermostable vaccines
UK-based synthetic biology firm Prokarium has secured $10 million from Saudi, Swedish and Korean investors to help drive clinical development of thermostable vaccines.
Read More
UK-based synthetic biology firm Prokarium has secured $10 million from Saudi, Swedish and Korean investors to help drive clinical development of thermostable vaccines.
Read More
